Oppenheimer & Co’s GSK GSK Stock Holding History

Oppenheimer & Co’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.38M	Sell	43,081 -1,277	-3%	-$69.2K	0.03%	538
2025 Q4	$2.18M	Buy	44,358 +842	+2%	+$39.3K	0.03%	527
2025 Q3	$1.88M	Sell	43,516 -4,065	-9%	-$159K	0.02%	627
2025 Q2	$1.83M	Buy	47,581 +1,768	+4%	+$67.6K	0.02%	610
2025 Q1	$1.77M	Sell	45,813 -1,271	-3%	-$46.5K	0.03%	578
2024 Q4	$1.59M	Sell	47,084 -19,561	-29%	-$704K	0.02%	621
2024 Q3	$2.72M	Buy	66,645 +4,204	+7%	+$172K	0.04%	450
2024 Q2	$2.4M	Sell	62,441 -4,230	-6%	-$178K	0.04%	467
2024 Q1	$2.86M	Sell	66,671 -2,928	-4%	-$121K	0.05%	418
2023 Q4	$2.58M	Sell	69,599 -22,195	-24%	-$797K	0.05%	429
2023 Q3	$3.33M	Buy	91,794 +900	+1%	+$31.9K	0.07%	321
2023 Q2	$3.24M	Sell	90,894 -128	-0.1%	-$4.59K	0.06%	330
2023 Q1	$3.24M	Sell	91,022 -1,875	-2%	-$65.6K	0.07%	317
2022 Q4	$3.26M	Sell	92,897 -3,826	-4%	-$127K	0.07%	308
2022 Q3	$2.85M	Sell	96,723 -24,099	-20%	-$913K	0.07%	337
2022 Q2	$6.57M	Buy	120,822 +35,435	+41%	+$1.96M	0.14%	161
2022 Q1	$4.65M	Buy	85,387 +3,134	+4%	+$170K	0.08%	286
2021 Q4	$4.53M	Sell	82,253 -6,460	-7%	-$336K	0.08%	290
2021 Q3	$4.24M	Buy	88,713 +2,845	+3%	+$143K	0.08%	302
2021 Q2	$4.27M	Buy	85,868 +2,658	+3%	+$128K	0.08%	300
2021 Q1	$3.71M	Buy	83,210 +6,380	+8%	+$290K	0.07%	311
2020 Q4	$3.53M	Sell	76,830 -3,091	-4%	-$142K	0.07%	301
2020 Q3	$3.76M	Sell	79,921 -1,787	-2%	-$89.5K	0.09%	246
2020 Q2	$4.17M	Buy	81,708 +15,442	+23%	+$792K	0.11%	212
2020 Q1	$3.14M	Buy	66,266 +7,368	+13%	+$393K	0.1%	231
2019 Q4	$3.46M	Buy	58,898 +2,125	+4%	+$118K	0.09%	269
2019 Q3	$3.03M	Sell	56,773 -983	-2%	-$50.6K	0.08%	277
2019 Q2	$2.89M	Sell	57,756 -9,078	-14%	-$456K	0.08%	290
2019 Q1	$3.49M	Sell	66,834 -243	-0.4%	-$12.1K	0.09%	248
2018 Q4	$3.2M	Sell	67,077 -14,392	-18%	-$709K	0.1%	223
2018 Q3	$4.09M	Sell	81,469 -819	-1%	-$41.6K	0.1%	214
2018 Q2	$4.15M	Sell	82,288 -11,344	-12%	-$571K	0.11%	207
2018 Q1	$4.57M	Buy	93,632 +33,790	+56%	+$1.57M	0.12%	192
2017 Q4	$2.65M	Sell	59,842 -14,151	-19%	-$654K	0.07%	316
2017 Q3	$3.75M	Sell	73,993 -6,829	-8%	-$346K	0.1%	240
2017 Q2	$4.36M	Buy	80,822 +1,983	+3%	+$106K	0.12%	210
2017 Q1	$4.16M	Buy	78,839 +2,815	+4%	+$143K	0.12%	212
2016 Q4	$3.66M	Sell	76,024 -2,858	-4%	-$141K	0.11%	224
2016 Q3	$4.25M	Buy	78,882 +3,108	+4%	+$170K	0.12%	189
2016 Q2	$4.1M	Sell	75,774 -1,730	-2%	-$91.1K	0.12%	192
2016 Q1	$3.93M	Sell	77,504 -11,746	-13%	-$585K	0.12%	196
2015 Q4	$4.5M	Sell	89,250 -13,780	-13%	-$702K	0.13%	173
2015 Q3	$4.95M	Sell	103,030 -419	-0.4%	-$21.8K	0.15%	162
2015 Q2	$5.39M	Sell	103,449 -18,112	-15%	-$1.02M	0.15%	161
2015 Q1	$7.01M	Buy	121,561 +41,517	+52%	+$2.38M	0.19%	121
2014 Q4	$4.28M	Buy	80,044 +23,753	+42%	+$1.33M	0.12%	194
2014 Q3	$3.23M	Buy	56,291 +16,557	+42%	+$1.02M	0.1%	251
2014 Q2	$2.66M	Sell	39,734 -3,663	-8%	-$248K	0.08%	294
2014 Q1	$2.9M	Sell	43,397 -1,888	-4%	-$128K	0.09%	280
2013 Q4	$3.02M	Buy	45,285 +683	+2%	+$44.3K	0.1%	255
2013 Q3	$2.8M	Buy	44,602 +6,099	+16%	+$393K	0.1%	258
2013 Q2	$2.41M	Buy	+38,503	New	+$2.44M	0.09%	267

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Oppenheimer & Co's GSK Position: Q1 2026 in Review

Oppenheimer & Co reduced its GSK (GSK) stake by 2.9% in Q1 2026, selling an estimated $69.2K and leaving 43,081 shares worth $2.38M. The position accounts for 0.03% of the portfolio, ranked #538.

Oppenheimer & Co first reported a position in GSK in Q2 2013 and has held it in 52 quarters since. The position peaked at $7.01M in Q1 2015. 1,033 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Oppenheimer & Co held 43,081 shares of GSK worth $2.38M as of Q1 2026.
Oppenheimer & Co sold 1,277 GSK shares in Q1 2026, an estimated $69.2K.
GSK made up 0.03% of Oppenheimer & Co's portfolio in Q1 2026, its #538 holding.
Oppenheimer & Co first reported a position in GSK in Q2 2013 and has held it in 52 quarters since.
Oppenheimer & Co's GSK position peaked at $7.01M in Q1 2015.
1,033 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.